Two molecular biomarkers–IDH mutational status and 1p/19q codeletion–were a major breakthrough to establish an integrated diagnosis criteria for diffuse gliomas, and were included in the 2016 WHO updated 4th Edition on CNS tumor classification [1]. Here, IDH1 is linked to central nervous system neoplasm.